-
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257 million (USD35 million) in revenues, a 146% year-on-year (YOY) increase. This growth was driven by the commercialization of the Toumai Laparoscopic Surgical Robot and SkyWalker Orthopedic Surgical Robot both domestically and internationally. Despite the revenue…
-
MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation. The company expects group revenues to increase by 10%, with the net loss staying below USD275 million, marking a 58% decrease from the same period last year. Overseas business revenues saw a significant surge of…
-
MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its coronary rapamycin drug balloon dilation catheter, Fireliums, for dilation treatment of primary coronary artery bifurcation stenosis. This approval marks a significant milestone in the commercialization of this…
-
MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its TomaHawk intravascular shock wave therapy device, disposable coronary intravascular shock wave catheter (TomaHawk coronary intravascular shock wave catheter system). This approval marks a significant milestone in the…
-
MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its FireRaptor coronary rotational atherectomy system. The system includes a rotational atherectomy instrument, disposable coronary artery rotational atherectomy catheter, and rotational atherectomy guide wire. First-Homegrown Coronary Rotational Atherectomy…
-
MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval
•
Shanghai-based medical device giant MicroPort Scientific Corp., (HKG: 0853) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its FireFalcon coronary spinous process balloon, a novel device designed to enhance vascular dilation in coronary intervention therapy. Challenges of Traditional Balloon Dilation TechniquesBalloon dilation…
-
MicroPort Scientific Corp.’s BonaFire Receives NMPA Approval as First Whole-Body MRI Safety Pacing Electrode Lead
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its whole-body magnetic resonance imaging (MRI) condition safety pacing electrode lead, BonaFire. This marks a significant milestone, as BonaFire becomes the first product of its…
-
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
•
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of its shares in Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), according to a Bloomberg report. The company is said to be working with financial advisors to assess its minority stake in MicroPort after…
-
MicroPort CardioFlow’s Heart Valve Balloon Dilatation Catheter Alwide Plus Gains Mexican Approval
•
MicroPort Scientific Corp., a leading Chinese medical device company (HKG: 0853), through its spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced that it has received market approval for its heart valve balloon dilatation catheter, Alwide Plus, from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in…
-
MicroPort Scientific’s Firesorb Bioabsorbable Stent Begins Clinical Use in China
•
MicroPort Scientific Corp., a leading medical device company based in Shanghai (HKG: 0853), has announced the initial clinical applications of its new-generation bioabsorbable stent, Firesorb, across seven clinical centers in five Chinese cities. The product received marketing approval in China in July this year. Firesorb is a bioabsorbable rapamycin targeted…
-
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
•
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), will acquire a 100% stake in Shanghai Heart Forever Medical Technology Co., Ltd. The acquisition, valued at up to RMB 380 million, will be executed through a transfer from its sister company,…
-
MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment
•
Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its proprietary bioabsorbable rapamycin eluting coronary stent system. This innovative device is designed for the treatment of patients suffering from ischemic heart disease due to…
-
MicroPort Scientific’s Fully Biodegradable Cardiac Stent Earns NMPA Nod
•
Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its new generation fully biodegradable and absorbable cardiac stent. This innovation marks a significant advancement in the field of interventional cardiology. The stent is the…
-
MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has entered into a distribution framework agreement with Dongguan Kewei Medical Instrument Co., Ltd. Kewei, which was acquired by MicroPort Scientific in 2012, has agreed…
-
MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) and spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) unveil their financial forecasts for the first half of 2024, along with business updates. MedBot anticipates a significant year-on-year…
-
MicroPort CardioFlow Medtech’s AltaValve Receives FDA Breakthrough Designation for Mitral Regurgitation Treatment
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has received Breakthrough Devices status from the US Food and Drug Administration (FDA) for its AltaValve transcatheter mitral valve replacement device. This product, co-developed with…
-
MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion
•
China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has secured the CE mark for its VitaFlow Liberty transcatheter aortic valve and its recyclable delivery system. This regulatory approval paves the way for the product’s market entry…
-
MicroPort CardioFlow Forecasts 31%-36% YOY Sales Growth for 2023 Driven by TAVI Product Expansion
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced a forecast for its 2023 financial performance along with key business updates. The company anticipates generating sales within the range of RMB 330 million to RMB 340 million for the year, reflecting…
-
MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System
•
MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its France-based subsidiary MicroPort Cardiac Rhythm Management Limited (MicroPort CRM) has received a market license from the National Medical Products Administration (NMPA) for its next-generation intravenous magnetic resonance conditionally safe implantable cardiac pacing system. The product…
-
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
•
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth forecast for its subsidiary Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), in which it holds a 40.32% stake. MicroPort Endovascular is anticipated to achieve revenues within the range of RMB 1.17-1.2 billion (USD 168-238…
